5 of Last Week's Biggest Losers

There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.

Company

March 28

Weekly Loss

Exelixis  (NASDAQ: EXEL  )

$3.38

46%

MannKind (NASDAQ: BOFI  )

$4.83

18%

Rally Software  (NYSE: RALY  )
(NASDAQ: SPLS  )

$13.69

16%

Kandi Technologies  (NASDAQ: KNDI  )

$16.14

15%

Organovo  (NYSEMKT: ONVO  )

$7.41

12%

Source: Barron's.

Let's start with Exelixis. The biotech shed nearly half of its value after a critical study of its cabozantinib in treating metastatic castration-resistant prostate cancer fell short of expectations. A more diversified biotech could withstand a hit like this, but a lot of the value in Exelixis was based on the the efficacy of this single drug.

MannKind investors and needle-weary diabetes sufferers are hoping that an inhaled insulin can improve their situations. However, an FDA staff review is raising concerns about MannKind's Afrezza. The treatment's impact on lung function is just one of the many concerns that may hold Afrezza back, and investors decided to take one not-so-small step back on MannKind.

Rally Software continued to sell off after posting disappointing quarterly results a week earlier. The provider of cloud-based solutions for managing Agile software development may have posted a narrower deficit than analysts were targeting, but its guidance was uninspiring. 

Kandi slumped after Jim Cramer passed on the opportunity to offer a bullish perspective. The stock came up during Mad Money's Lightning Round on Monday, but Cramer countered that he preferred a larger stateside maker of off-road vehicles. Naturally Kandi bulls will argue that the comments miss the mark. Kandi's appeal has been in the electric cars that it's now working on and growing participation in Chinese auto-sharing offerings.   

Organovo stumbled despite presenting at the 2nd Annual Regen Med Investor Day on Wednesday. Organovo has a great story to tell. It's toiling away on 3-D proxies of human tissues that could be used for medical research and therapeutic applications. The stock's been volatile, and even after this past week's sell-off it has still nearly tripled since the start of last year.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? Consider that David Gardner has proved the critics wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.



Read/Post Comments (3) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 30, 2014, at 8:59 AM, larryw101 wrote:

    This clown author never has anything worthwhile to say. He makes articles out of nothing.

    Any one can report which stocks lost share price the week before. This clown makes a whole article of it and he does it all the time.

    It's like writing a story about last week's weather.

    Typical garbage journalism (if even that) from Motley.

    This clown needs some other source of income than his pennies-a-click he gets from readers.

    Thanks again Motley for wasting my time.

  • Report this Comment On March 30, 2014, at 9:56 AM, WCoastGuynCA wrote:

    If you owned any of these and want to recoup some losses I suggest you check out Amarantus Bioscience (AMBS) before the open tomorrow. It's currently trading under a dime.

    Expected to launch the first commercial test to detect early stage Alzheimer's before the end of the year. Currently working with Becton Dickinson.

    Twitter: @AmarantusBio ....9,775 followers

  • Report this Comment On March 30, 2014, at 3:14 PM, yuya wrote:

    Exelixis was a Motley's stock and recommended as one of the future biotechs.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2895824, ~/Articles/ArticleHandler.aspx, 8/22/2014 11:59:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement